[The logo is protected from the company]
We are developing and commercializing novel, proprietary products and technologies that are intended to make the blood supply safer. We are commercializing the INTERCEPT Blood System for platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT Blood System for platelets and plasma is not yet approved for sale in the United States. In 2008, we initiated a Phase I clinical trial for our INTERCEPT Blood System for red blood cells in the United States. The INTERCEPT Blood System, which is based on our proprietary Helinx technology for controlling biological replication, is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells.
|Address||Global Headquarters 2550 Stanwell Drive Concord, California USA 94520|
|Holding||No Holding Details|
Open Jobs - Cerus Corporation
Currently there are no opneings at Cerus Corporation
Cerus Corporation Reviews